ARTICLE | Company News
GlycoDesign, Seikagaku Corp. deal
February 10, 2003 8:00 AM UTC
GD regained IP and marketing rights from Seikagaku to Core 2 transferase inhibitors under the companies' 1999 research collaboration. GD said it will develop the compounds internally for anti-inflammatory conditions. ...